pharma · Muscle-invasive bladder cancer · Unresectable intrahepatic cholangiocarcinoma
Ningbo Cancer Hospital
Ningbo Cancer Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Muscle-invasive bladder cancer, Unresectable intrahepatic cholangiocarcinoma, Head and neck squamous cell carci
Company details
- Status
- Public
- HQ
- CN
- Programs
- 120
- Drugs
- 183
- Patents
- 0
TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN
Phase 2 · small molecule · Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.
TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN for Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication. is a Phase 2 program (small_molecule) at Ningbo Cancer Hospital with 1 ClinicalTrials.gov record(s).
Internal code UC-BCG-2503
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ningbo Cancer Hospital
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.
- Status
- active
- Trials
- 1